Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry
![FXR deficiency impairs hepatic retinoid storage. Whole body FXR-null... | Download Scientific Diagram FXR deficiency impairs hepatic retinoid storage. Whole body FXR-null... | Download Scientific Diagram](https://www.researchgate.net/publication/338070038/figure/fig1/AS:959575746441219@1605792094565/FXR-deficiency-impairs-hepatic-retinoid-storage-Whole-body-FXR-null-mice-and-age-match.png)
FXR deficiency impairs hepatic retinoid storage. Whole body FXR-null... | Download Scientific Diagram
![Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study](https://www.natap.org/2020/images/112420/112420-2/1124201.gif)